The Anti-tumor Effect of Metformin And Atorvastatin in Breast Cancer
NCT ID: NCT05507398
Last Updated: 2022-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
100 participants
INTERVENTIONAL
2022-10-31
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control group
30 patients who will serve as a control group and will receive placebo tablets
Placebo, metformin and atorvastatin
comparing the anti-tumor effects of metformin and atorvastatin
metformin group
30 patients who will receive metformin 1000 mg/day.
Placebo, metformin and atorvastatin
comparing the anti-tumor effects of metformin and atorvastatin
atorvastatin group
30 patients who will receive atorvastatin 20 mg/day.
Placebo, metformin and atorvastatin
comparing the anti-tumor effects of metformin and atorvastatin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo, metformin and atorvastatin
comparing the anti-tumor effects of metformin and atorvastatin
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with no contraindication for chemotherapy, metformin, or statins
* Females aged ≥ 18 years old
* Performance status \< 2 according to the Eastern Cooperative Oncology Group (ECOG) score
Exclusion Criteria
* Pregnant or lactating women.
* Patients with hepatic or renal impairment.
* Patients with myopathy.
* Patients with any condition predispose to acidosis (COPD, heart failure, ….)
* Patients who had dementia, mental retarded, and any psychiatric condition that would prohibit the understanding or signing of informed consent.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Hassan Mohammed El-Abd
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ahmed elabd, doctor
Role: PRINCIPAL_INVESTIGATOR
Tanta university, faculty of pharmacy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Breast cancer treatment
Identifier Type: -
Identifier Source: org_study_id